This 20 minute session unpacks the implications of G1/23 and explores how recent Board of Appeal decisions are reshaping product launch strategies in Europe. Gain practical insights into how these rulings affect exclusivity, regulatory interplay, and the timing of market entry.
Speaker(s):

James Horgan
Chief IP Counsel- Policy & Litigation
MSD

Carsten Richter
Head of IP
Euroimmun
Time:
15:15pm - 15:35pm
Session Type:
Panel